Astrana Health Q1 revenue beats estimates

Astrana Health

07/05/2026 22:22

Overview

US physician-centric healthcare firm's Q1 revenue rose 56% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose 76% yr/yr to $0.74, driven by new full-risk contracts

Outlook

Astrana Health sees Q2 2026 revenue between $965 mln and $1 bln

Company expects Q2 2026 adjusted EBITDA of $65 mln to $70 mln

Result Drivers

FULL-RISK CONTRACTS - Co said performance was supported by conversion of key contracts to full-risk arrangements, with about 80% of Care Partners capitation revenue and 40% of consolidated membership now in full-risk models

OPERATING LEVERAGE - Management cited continued operating leverage and strong medical cost performance as drivers of Q1 results

Company press release: ID:nPn1ff8qva

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$965.1 mln
$949.21 mln (10 Analysts)
Q1 EPS
$0.29
Q1 Income from Operations
$28.5 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Astrana Health Inc is $38.00, about 7.8% above its May 6 closing price of $35.25

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)